Following the successful preclinical studies of this inhibitor in mouse models, an international, open-label, phase 1/2 trial was launched to investigate the safety and tolerability of enasidenib in patients with relapsed or refractory IDH2-mutant AML [143]. Here, IDH2 is linked to acute myeloid leukemia.